Personalised medicines in India by K&H Clinic

K&H Personalised Medicine Clinic has launched medical genomics based personalised health assessment and treatment protocol in India. 

The rapidly evolving field of medical genomics will create a new paradigm in the way healthcare services are rendered in the years to come. It is practiced in medical institutions like Mayo, Harvard and Stanford universities. Hyderabad in India is the only city to boast of such high end medical care now.

Medical genomics in a nutshell is about analysing our genes (DNA) to look at the root cause for the pathogenesis of any disease process. There are umpteen advantages of testing the genome and in pre-empting the disease. It helps to predict the disease process before it happens and enables to prevent it before hand.

Above all, we can determine the right medication which works best, depending on our genome without producing much side effects, and the right dosage to be administered at the right time. This makes the current trial and error medication redundant, to the advantage of the patient.

Personalised medicine based on medical genomics works on the principle that not everybody should be treated the same way or put into boxes depending on the symptoms and diagnosis. Each one of us is unique and have different genetic composition, therefore one size does not fit all. Calibrating the medicine and dose as per the need brings in precision treatment and prevents ill effects of wrong and excess dosage. 

Often the current protocols for prescribing medicines are based on trials done on Western populace, their genomic composition and the pattern their bodies react to treatment is disparate from our population. Medical genomics addresses this concern by bringing in accuracy in administering medication and therefore the medical fraternity strongly believes that the future of modern medicine lies in medical genomics.

Extensive research is on in countries like Europe, UK, Canada, Australia, USA, with the help of the government to obtain worldwide genome analysis and make medical genomics mainstream medical treatment. 

“Our population is much younger and the need for preventive medicine and personalised treatments is more than the developed countries. If we do not act pre-emptively and prevent the disease within the next 20 to 30 years, the burden could become enormous  and unmanageable, even as the healthcare expenses skyrocket,” opines Dr Hima Jyothi, professional in medical genomics from Harvard University.

Reference: Pharmabiz